EDS eBook

While the reasons for clinical failure vary, a large portion is due to issues with safety and efficacy. Unwanted immunogenicity can have severe consequences for patients, this is why understanding the potential immunogenicity and immunotoxicity of your candidate is a regulatory requirement to support your first-in-human program. As the biopharmaceutical developer, it is your responsibility to ensure you have adequately assessed the possibility of your drug candidate eliciting an unwanted immune response. Unfortunately, immunogenicity assessment is also an area where “standard” in vivo toxicology assessments might lack clinical relevance. To overcome this challenge, read our ebook and get an expert view on the challenges of early immunosafety assessment and available risk mitigation strategies.

By clicking "Access Content" you agree to our Legal Disclaimer and the Lonza Privacy and Cookies Policy.

Latest content
Latest briefing from the Knowledge Center